TBH Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Procedure-driven DemandTeleflex’s consumables-oriented model links demand to recurring hospital procedures and product replacement. This supports revenue durability and customer retention, although growth still depends on procedure volumes, product adoption and hospital purchasing decisions.
Core Segment Growth And InnovationGrowth in vascular and surgical franchises, combined with EZPLAZ approval and Freesolve milestones, strengthens Teleflex’s specialty portfolio. New clinically differentiated products can expand adoption, support mix and reinforce its position in critical-care markets.
Portfolio Focus And Debt ReductionExiting OEM sharpens focus on core medical technology franchises while releasing capital for debt repayment. Lower leverage can reduce interest costs and improve strategic flexibility, allowing greater investment in higher-priority products and commercial execution.
Bears Say
Severely Weakened ProfitabilityThe sharp shift from historical profitability to substantial losses is the most material fundamental risk. Persistent margin pressure, charges or unfavorable mix could impair reinvestment capacity and make earnings recovery dependent on successful restructuring and execution.
Integration And Growth Execution RiskDelayed order-to-cash, distributor and sales-force integration indicates execution complexity in a strategically important segment. If disruptions persist through 2026, they may constrain organic growth, dilute customer relationships and delay expected benefits from the acquisition.
Higher Leverage And Weaker Cash CoverageLeverage has increased materially while cash-flow coverage has weakened versus prior years. Although debt repayment improves the trajectory, the combination of negative earnings and lower liquidity coverage limits financial flexibility if operating recovery or divestiture timing falls short.
Teleflex News
TBH FAQ
What was Teleflex’s price range in the past 12 months?
Currently, no data Available
What is Teleflex’s market cap?
Teleflex’s market cap is CHF4.47B.
When is Teleflex’s upcoming earnings report date?
Teleflex’s upcoming earnings report date is Oct 22, 2026 which is in 63 days.
How were Teleflex’s earnings last quarter?
Teleflex released its earnings results on Aug 06, 2026. The company reported $1.432 earnings per share for the quarter, beating the consensus estimate of $1.042 by $0.39.
Is Teleflex overvalued?
According to Wall Street analysts Teleflex’s price is currently Undervalued.
Does Teleflex pay dividends?
Teleflex does not currently pay dividends.
What is Teleflex’s EPS estimate?
Teleflex’s EPS estimate is 1.55.
How many shares outstanding does Teleflex have?
Currently, no data Available
What happened to Teleflex’s price movement after its last earnings report?
Teleflex reported an EPS of $1.432 in its last earnings report, beating expectations of $1.042. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Teleflex?
Currently, no hedge funds are holding shares in CH:TBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teleflex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF126.85 (― Upside)
CHF126.85 (― Upside)
Blogger Sentiment
Bullish
CH:TBH Sentiment 67%
Sector Average 62%
Sector Average 62%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.98%
Trailing 12-Months
Company Description
Teleflex
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
TBH Company Deck
TBH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic outlook: management reported a quarter that beat on revenue, margin and EPS expectations, closed a sizable OEM divestiture generating ~$1.5B of proceeds to accelerate debt paydown and share repurchases, and highlighted meaningful innovation and R&D progress (EZPLAZ approval, Freesolve milestones). However, the company is navigating near-term headwinds — primarily slower-than-expected integration of the VI acquisition that pressured Interventional revenue, margin compression from tariffs and acquisition mix, stranded costs and regulatory timing on remaining divestitures. Management reiterated a clear plan to reduce debt, return capital, increase R&D focus and deliver margin improvement in 2027, and raised FY EPS guidance while trimming FY revenue growth guidance. On balance, the positive strategic moves, capital returns and innovation progress outweigh the transient integration and margin challenges, with improved financial profile expected in 2027.View all CH:TBH earnings summariesTBH Stock 12 Month Forecast
Average Price Target
―Haemonetics
―
ICU Medical
―
Lemaitre Vascular
―
Merit Medical Systems
―
Bausch + Lomb Corporation
―